Understanding their mechanism of action provides a framework for optimizing efficacy, minimizing side effects, and expanding applications beyond diabetes to include other areas such as the treatment of obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), and even neurodegeneration
Another study performed by the same authors revealed that treatment with AICAR, an AMPK-activator, diminished ROS accumulation in pancreatic acinar cells (Srinivasan 2021)
doi: 10.1002/oby.21068, 118 PuhlR
continued treatment helps maintain losses Common side effects that may affect treatment adherence include: Nausea and vomiting (usually temporary, improving after several weeks) Diarrhoea or constipation Abdominal discomfort Fatigue Injection site reactions Important safety considerations include: Risk of hypoglycaemia if used with insulin or sulfonylureas [4] Do not stop or reduce insulin rapidly without medical advice (risk of diabetic ketoacidosis) [4] Maintain adequate hydration to prevent acute kidney injury [4] Potential for gallbladder problems (pain, stones) Rare risk of intestinal obstruction Possible worsening of diabetic retinopathy in people with diabetes during rapid improvement in blood glucose For tirzepatide: use additional non-oral contraception for 4 weeks after initiation and each dose escalation Patients should contact their GP if they experience: persistent vomiting preventing fluid intake, severe abdominal pain, signs of gallbladder disease, or unusual thyroid symptoms
On the other hand, chelerythrine has other effects, for example, it can affect multiple ion channels in cardiac tissue in a pkc-independent manner (Son et al., 2011), but also anti-inflammatory effects via a pkc mechanism, with pkc acting as an upstream regulator of the pro-inflammatory PKC/NF-kappaB pathway (Zeng et al., 2015)
